Alignment Healthcare (ALHC)

• Market cap: $2.79B
• 1 day: -0.07%
• 5 days: 5.73%
• 1 month: 36.04%
• 3 months: 39.43%
• 6 months: 46.73%
• Year to date: 26.04%
• 1 year: 95.31%
• 5 years: -15.83%
• 10 years: -15.83%
• Sector: Financials
• Industry: Hospital & Medical Service Plans

About: Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which customers receive healthcare coverage and services on an annual basis. The company combines a technology platform and clinical model for more effective health outcomes.

Employees: 1,536

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 10

83% more call options, than puts

Call options by funds: $255K | Put options by funds: $139K

50% more capital invested

Capital invested by funds: $1.32B [Q2] → $1.97B (+$652M) [Q3]

15% more funds holding

Funds holding: 118 [Q2] → 136 (+18) [Q3]

5% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 42

0% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]

0.99% less ownership

Funds ownership: 88.08% [Q2] → 87.09% (-0.99%) [Q3]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $8 45% downside
• Avg. target: $13.20 9% downside
• High target: $17 17% upside

5 analyst ratings

• positive: 3 60%
• neutral: 1 20%
• negative: 1 20%

Stifel Craig Jones 63% 1-year accuracy 5 / 8 met price target	10% upside $16	Buy Maintained	14 Jan 2025
Stephens & Co. Scott Fidel 56% 1-year accuracy 22 / 39 met price target	17% upside $17	Overweight Reiterated	2 Jan 2025
TD Cowen Gary Taylor 21% 1-year accuracy 4 / 19 met price target	11% downside $13	Buy Maintained	31 Oct 2024
Barclays Andrew Mok 30% 1-year accuracy 19 / 63 met price target	45% downside $8	Underweight Maintained	30 Oct 2024
UBS Kevin Caliendo 65% 1-year accuracy 11 / 17 met price target	18% downside $12	Neutral Maintained	30 Oct 2024